We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





Opioid Drug Abuse Testing Key Topic at Congress

By LabMedica International staff writers
Posted on 08 Jun 2017
Development of new diagnostic procedures for opioid drugs and augmenting communication pathways between laboratory, clinician, and patient are important topics that will be addressed at the July 30 to August 3, 2017, AACC Annual Meeting & Clinical Lab Expo (San Diego, CA, USA).

In the United States - according to data reported in the December 2016 issue of the journal Morbidity and Mortality Weekly Report - opioids accounted for more than two-thirds of all drug overdose deaths in 2015, 15.6% more than the previous year, and drug overdose deaths nearly tripled between 1999 and 2014.

While official agencies and medical groups recommend clinical laboratory tests to support efforts aimed at curbing opioid drug abuse, many physicians may not be fully equipped with the knowledge required to interpret this test data for their patients. More...
To help in this regard, nationally recognized centers, such as the Mayo Clinic (Rochester, MN, USA) have entered the limelight.

Physician requests for assistance in interpreting pain management tests at the Mayo Clinic increased after the [U.S.] Centers for Disease Control and Prevention (Atlanta, GA, USA) issued guidelines in March 2016 recommending urine drug testing before starting patients on opioid therapy and for monitoring them afterward. This guideline and others are driving the testing, but also leading to more confusion in terms of which type of laboratory tests to use - for example, immunoassays versus definitive methods - which specific tests to include, the frequency, and how to interpret those tests.

To help out, the Mayo Clinic now deploys many tools to help providers navigate the nuances of drug testing. Mayo’s online test catalog includes a primer on interpreting drug tests for compliance, along with short “hot topic” videos and other online educational tools.

Other institutions are also rising to the challenge. Vanderbilt University (Nashville, TN, USA) for example, now makes it possible for physicians to request interpretative services at the time they order a test.

In response to the opioid crisis, discussions at the AACC Annual Meeting will emphasize that clinical labs and their physician clients need to work together to stay abreast of drug testing needs in their local communities.

Related Links:
AACC Annual Meeting & Clinical Lab Expo
Mayo Clinic
Centers for Disease Control and Prevention
Vanderbilt University

Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.